This whitepaper focuses on Boehringer Ingelheim’s development and manufacturing facility in China. As one of the world’s leading organizations in the area of biopharmaceutical contract manufacturing, Boehringer Ingelheim is the first multi-national pharmaceutical company that brings over 30 years of experience in biopharmaceutical contract manufacturing to China, to better serve patients and the biopharmaceutical industry – both in China and in the world.

As a pioneer in biopharmaceuticals with more than 35 years of experience the company has brought more than 20 biologic medicines to patients around the world. Boehringer Ingelheim Biopharmaceuticals supplies the Boehringer Ingelheim in-house development pipeline and marketed products Metalyse®, Actilyse®, Imukin® and Beromun®, as well as the contract manufacturing business, known as Boehringer Ingelheim BioXcellence™. Boehringer Ingelheim Biopharmaceuticals operates four best in-class biopharmaceutical development- and manufacturing facilities in Biberach (Germany), Vienna (Austria), Fremont (USA) and Shanghai (China).